Drug Profile


Alternative Names: ACR-16; ASP 2314; FR-310826; Huntexil; TV-7820

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator NeuroSearch Sweden AB
  • Developer NeuroSearch Sweden AB; Teva Pharmaceutical Industries
  • Class Antiparkinsonians; Antipsychotics; Neuropsychotherapeutics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Glutamate modulators; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Huntington's disease
  • Discontinued Parkinson's disease; Schizophrenia

Most Recent Events

  • 22 Apr 2017 Efficacy data from the phase II Pride-HD in Huntington's disease presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 17 Mar 2017 Teva Branded Pharmaceutical Products, R&D initiates a phase I trial for Huntington’s disease in Germany (PO, Capsule) (NCT03019289)
  • 11 Jan 2017 Teva Branded Pharmaceutical Products, R&D plans a phase I trial for Huntington’s disease in Germany (PO, Capsule) (NCT03019289)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top